



COLORADO

Department of Health Care
Policy & Financing

AGENDA

Pharmaceuticals & Therapeutics Committee

Department of Health Care Policy & Financing

Zoom Webinar Registration: TBA
Tuesday, January 10, 2023, 1:00-5:00 P.M.

1. Committee Member Introductions

Introduction of New Members
Vote for Committee Positions - Chairperson, Vice Chairperson

2. Unfinished Business and General Orders

Approval of minutes from October 4, 2022 P&T meeting
Updates from October 4, 2022 P&T Meeting
Hepatitis C Virus Treatments
Direct Acting Antivirals, Ribavirin
Human Immunodeficiency Virus (HIV) Treatments
Intranasal Rhinitis Agents
Targeted Immune Modulators
Asthma, Other Agents
Newer Hereditary Angioedema (HAE) Products

Mass review drug classes:

Antibiotics, Inhaled
Antiherpetic Agents
Oral, Topical
Fluoroquinolones, Oral
Immune Globulins
Antihistamines
Newer Generation, Antihistamine/Decongestant Combinations
Leukotriene Modifiers
Methotrexate Products
Epinephrine Products
Respiratory Agents
Inhaled Anticholinergics & Combinations
Inhaled Beta2 Agonists (Short & Long-Acting)
Inhaled Corticosteroids & Combinations
Phosphodiesterase Inhibitors (PDEIs)

3. New Business

Updates from the Prior Authorization Call Center

Improving health care equity, access, and outcomes for the people we serve while
saving Coloradans money on health care and driving value for Colorado.
www.colorado.gov/hcpf



4. Drug Classes Up for Review

Review of Opioids - Short-Acting, Fentanyl Preparations, Long-Acting
Review of Anticonvulsants, Oral
Review of Newer Generation Antidepressants
Review of Neurocognitive Disorder Agents
Review of Sedative Hypnotics
Review of Skeletal Muscle Relaxants
Review of Stimulants and Related Agents
Review of Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral
Review of Multiple Sclerosis Therapies - Disease Modifying & Symptom Management
Review of Ophthalmics, Immunomodulators

Mass review drug classes:

- Non-Opioid Analgesia Agents - Oral & Topical
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Anti-Parkinson's Agents
- Benzodiazepines (Non-Sedative Hypnotic)
- Anxiolytics, Non-Benzodiazepine
- Atypical Antipsychotics - Oral/Topical
- Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
- Lithium Agents
- Ophthalmics, Allergy
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.



- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com and carbon copy: Brittany Schock, PDL Pharmacist, brittany.schock@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **January 3rd, 2023 by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: April 4, 2023.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

